 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/613412
Cardiology - Acute Coronary Syndrome, Anticoagulants
|
Description: |
This report provides in-depth analysis of the market and pipeline from the perspective of global thought leaders.
This report is based on a series of seven full interviews with US Thought Leaders (emergency medicine, orthopedic surgery, interventional cardiology, electrophysiology), and supporting comments from our last interventional CV report (January 2008). This Panel convened shortly after ACC 2008. In an era of greater restrictions on detailing to physicians we asked our Panel to outline the differences that they see in reps who market drugs and devices. The Panel provided general comments and specific real-world examples on how hospital-based reps are influencing their prescribing behavior.
One of the key drawbacks to warfarin is the need for INR monitoring. The Panel discusses the new in-home INR options.
The Panel next focused on the role of interventional and medical therapy in acute coronary syndrome. The discussion covered a broad array of stents (drug eluting vs. bare metal) and anticoagulants and their interplay in the emergency room, the cath lab, the EP lab, the orthopedic surgical theater and the post-hospital environment. Each Panelist shares a perspective on the balance between restenosis, anticoagulant effects, risks of DVT/PE and bleeding.
In order to understand the issues surrounding post-operative surgical bleeding, we also spoke with an orthopedic surgeon specializing in “high profile injuries” for a number of major US sports teams. Finally, we received input into a variety of devices and new drugs targeting atrial arrhythmias
The drugs discussed by the Panel include: Lovenox (enoxaparin; Sanofi-Aventis), Arixtra (fondaparinux; GSK), Coumadin (warfarin; BMS), Exanta (ximelagatran; AstraZeneca), Pradaxa (dabigatran; Boehringer Ingelheim), Xarelto (rivaroxaban; Bayer, J&J), idraparinux (Sanofi-Aventis), SSR-126517
(Sanofi-Aventis), apixaban (BMS / Pfizer), YM-150 (Astellas), betrixaban (PRT054021; Portola), DU-176b (Daiichi Sankyo), AZD0837 (AstraZeneca), PD-0348292 (Pfizer), otamixaban (Sanofi-Aventis), LY517717 (Lilly), flovagatran (TGN 255; Trigen), Angiomax (bivalirudin; The Medicines Company), AVE-5026 (Sanofi-Aventis), Plavix (clopidogrel; S-A, BMS), Aggrenox (aspirin/dipyridamole; Boehringer-Ingelheim), Effient (prasugrel; Daiichi Sankyo / Lilly), cangrelor (The Medicines Company); ticagrelor (AZD-6140; AstraZeneca), SCH530348 (Thrombin Receptor Antagonist; Schering-Plough), DZ-697b (Daiichi-Sankyo), Ranexa (ranolazine; CV Therapeutics), Micardis (telmisartan), Multaq (dronedarone; Sanofi-Aventis), Kynapid (vernakalant; Astellas/Cardiome), azimilide (Procter & Gamble), Cypher (Cordis), Taxus (Boston Scientific), Endeavor (Zotarolimus-Eluting Coronary Stent; Medtronic), Xience Vision (Abbott) ; Promus (Boston Scientific), Export (Medtronic), Pronto (Vascular Solutions), AngioJet (Possis), Helex Septal Occluder (Gore), INRatio (Hemosense/Inverness), CoaguChek XS (Roche), Laser Ablation (Cardio Focus), GENius™ RF Multi-Channel generator (Ablation Frontiers), Mesh Electrode (Bard), Arctic Front (CryoCath Technologies), PLAATO™ System (ev3), WATCHMAN LAA (Atritech) |
|
Contents: |
- Executive Summary
- Bulleted Highlights
- Detailing in the Hospital
- Diagnostics
- Acute Coronary Syndrome
- Anticoagulants
- Heparins and Antithrombotics
- Antiplatelets
- Arrhythmia
- Key Findings
- Detailing in the Hospital
- General Comments
- Specific Examples
- Helex Septal Occluder (Gore)
- Plavix (clopidogrel; BMS)
- Effient (prasugrel; Lilly / Daiichi-Sankyo)
- Ranexa (ranolazine; CV Therapeutics)
- Diagnostics
- In-Home INR
- INRatio (Hemosense/Inverness); CoaguChek XS (Roche)
- Acute Coronary Syndrome
- Stents
- STEMI
- Late Stent Thrombosis; Drug Eluting vs. Bare Metal
- Xience Vision (Abbott) ; Promus (Boston Scientific)
- Endeavor (Zotarolimus-Eluting Coronary Stent; Medtronic)
- Taxus (Boston Scientific)
- Export (Medtronic) / Pronto (Vascular Solutions) / AngioJet (Possis)
- Anticoagulants
- ER Perspective
- Cath Lab Perspective
- Orthopedic Surgeon’s Perspective
- Electrophysiology Perspective
- Vitamin K Inhibitors
- Coumadin (warfarin; BMS)
- Antithrombotics
- Lovenox (enoxaparin; Sanofi-Aventis)
- Arixtra (fondaparinux; GSK)
- Angiomax (bivalirudin; The Medicines Company)
- Otamixaban (Sanofi-Aventis)
- Pharmaceutical Competitive Intelligence – Market Research – Conference Coverage
- Idraparinux (Sanofi-Aventis)
- SSR-126517 (Sanofi-Aventis)
- AVE-5026 (Sanofi-Aventis)
- Flovagatran (TGN 255; Trigen)
- Exanta (ximelagatran; AstraZeneca)
- Pradaxa (dabigatran; Boehringer Ingelheim)
- Xarelto (rivaroxaban; Bayer / J&J)
- apixaban (Bristol-Myers Squibb/Pfizer)
- YM-150 (Astellas)
- betrixaban (PRT054021; Portola)
- DU-176b (Daiichi Sankyo)
- AZD0837 (AstraZeneca)
- PD 0348292 (Pfizer)
- LY517717 (Lilly)
- Antiplatelets
- Plavix (clopidogrel; Sanofi-Aventis / Bristol-Myers Squibb)
- Clopidogrel +/- Telmisartan (PRoFESS trial)
- Aggrenox (aspirin/dipyridamole; Boehringer-Ingelheim)
- Effient (prasugrel; Lilly / Daiichi)
- Ticagrelor (AZD-6140; AstraZeneca)
- SCH530348 (Thrombin Receptor Antagonist; Schering-Plough)
- DZ-697b (Daiichi-Sankyo)
- Cangrelor (The Medicines Company)
- PRT060128 (Portola)
- Antiarrhythmics
- Devices for Ablation
- Laser Ablation: Cardio Focus
- RF Ablation: GENius™ RF Multi-Channel generator (Ablation Frontiers)
- Mesh Electrode (Bard)
- Arctic Front (CryoCath Technologies)
- PLAATO™ System (ev3) / WATCHMAN LAA (Atritech)
- Atrial Defibrillators
- Pharmacotherapy
- Multaq (dronedarone; Sanofi-Aventis)
- Kynapid (vernakalant; Cardiome / Astellas)
- Azimilide
- Thought-Leader Discussions
- Interview CV02023
- Interview CV02027
- Interview CV02030
- Interview CV02032
- Interview CV02034
- Interview CV02036
- Interview CV02041 |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/613412
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 12/10/2008 12:43:21 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Cardiology - Acute Coronary Syndrome, Anticoagulants
|
|
Web Address: |
http://www.researchandmarkets.com/reports/613412
|
|
Office Code: |
|
OCHKFKJNROQ
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Enterprisewide
|
|
€5,141.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
Page 2 of 2
Printed 12/10/2008 12:43:21
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
|
|
|
|
